- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IPI LEGACY LIQUIDATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,026 | -4,48 % | MEDIGENE AG stürzt ab - ich traue meinen Augen kaum! | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 1,015 | -1,31 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| MAINZ BIOMED | 1,020 | +6,08 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika
18.11.2025... ► Artikel lesen | |
| INFLARX | 1,026 | -1,91 % | InflaRx reports positive phase 2 results for HS and CSU treatments | ||
| VIKING THERAPEUTICS | 29,770 | -1,00 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,830 | -6,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 | Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property... ► Artikel lesen | |
| IBIO | 0,940 | -4,08 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,055 | +3,94 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| ATAI BECKLEY | 3,175 | -4,85 % | Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato | ||
| ALDEYRA | 4,597 | +1,17 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,370 | -1,24 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI in NPDR | First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global... ► Artikel lesen | |
| ARDELYX | 4,976 | +4,34 % | Raymond James raises Ardelyx stock price target to $15 on strong Ibsrela growth | ||
| CAPRICOR | 3,835 | -4,48 % | Capricor presents scalable framework for loading therapeutics into exosomes | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen |
IPI LEGACY LIQUIDATION CO gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IPI LEGACY LIQUIDATION CO finden Sie auf Wallstreet Online.